How Uropathogenic E. coli Attach to the Urothelium
Placeholder: fimbrial tip adhesins recognize host sugar receptors.
- Type 1: Fimbriae type (Placeholder short note)
- FimH: Adhesin protein (Placeholder short note)
- Mannose: Receptor sugar (Placeholder short note)
- ~80%: UTI cause share (Placeholder short note)
FimH tip-adhesin lectin binding
Placeholder: FimH lectin domain binds mannosylated uroplakin receptors.
Catch-bond shear strengthening
Placeholder: flow shear force strengthens the FimH-mannose bond.
Proanthocyanidins Reshape Bacterial Fimbriae
Placeholder: A-type PACs from cranberry hinder fimbrial adhesion.
- A-type PAC: Active compound (Placeholder short note)
- 36 mg/day: Typical dose (Placeholder short note)
- Steric block: Mechanism (Placeholder short note)
- Modest: Cochrane verdict (Placeholder short note)
Anti-adhesive PAC action
Placeholder: PACs alter fimbrial conformation, reducing binding rate.
Dose and standardization issues
Placeholder: product PAC content varies widely across brands.
D-Mannose Competitively Saturates FimH
Placeholder: free mannose sugar outcompetes host receptor mannose.
- D-mannose: Active compound (Placeholder short note)
- 2 g/day: Typical dose (Placeholder short note)
- Competitive: Mechanism (Placeholder short note)
- Renal: Excretion route (Placeholder short note)
FimH lectin-site saturation
Placeholder: excess mannose occupies FimH pockets before bacteria adhere.
Urinary concentration kinetics
Placeholder: rapid renal clearance concentrates mannose in urine.
Comparing Cranberry and D-Mannose Trial Effect Sizes
Placeholder: RCT quality and effect sizes differ between supplements.
- ~26%: Cranberry RRR (Placeholder short note)
- ~50%: Mannose RRR (Placeholder short note)
- Uneven: Trial count (Placeholder short note)
- Low-Mod: Evidence grade (Placeholder short note)
Cochrane cranberry meta-analysis
Placeholder: pooled RCTs show modest, heterogeneous benefit.
D-mannose trial limitations
Placeholder: fewer, smaller trials limit certainty of estimates.
Real-World Preventive Value Depends on Adherence
Placeholder: benefit scales with supplement choice and adherence.
- ~50%: Best case reduction (Placeholder short note)
- Large: Adherence effect (Placeholder short note)
- Adjunct: Guideline status (Placeholder short note)
- Favorable: Safety profile (Placeholder short note)
Adherence-weighted protection
Placeholder: irregular dosing sharply lowers effective protection.
Placement in prevention strategy
Placeholder: used alongside hydration and hygiene measures.
Placeholder: neither replaces antibiotics for active infection.